These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 26742542)

  • 1. Newer antiplatelet agents in acute coronary syndrome.
    Ferro A
    BMJ; 2016 Jan; 352():h7025. PubMed ID: 26742542
    [No Abstract]   [Full Text] [Related]  

  • 2. Prasugrel and Ticagrelor: the Romulus and Remus of Antiplatelet Therapy?
    Cammisotto V; Biondi-Zoccai G; Frati G; Giordano A
    Am J Cardiovasc Drugs; 2019 Aug; 19(4):377-379. PubMed ID: 31030412
    [No Abstract]   [Full Text] [Related]  

  • 3. Head to head comparison of Prasugrel versus Ticagrelor in patients with acute coronary syndrome: a systematic review and meta-analysis of randomized trials.
    Bundhun PK; Shi JX; Huang F
    BMC Pharmacol Toxicol; 2017 Dec; 18(1):80. PubMed ID: 29233189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The ISAR-REACT 5 trial: is there a winner between prasugrel and ticagrelor in acute coronary syndromes?].
    Ferlini M; Galvani M; Visconti LO
    G Ital Cardiol (Rome); 2020 Mar; 21(3):171-174. PubMed ID: 32100728
    [No Abstract]   [Full Text] [Related]  

  • 5. Impact of immature platelets on platelet response to ticagrelor and prasugrel in patients with acute coronary syndrome.
    Bernlochner I; Goedel A; Plischke C; Schüpke S; Haller B; Schulz C; Mayer K; Morath T; Braun S; Schunkert H; Siess W; Kastrati A; Laugwitz KL
    Eur Heart J; 2015 Dec; 36(45):3202-10. PubMed ID: 26216931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Which antiplatelet agent for whom? Which patient populations benefit most from novel antiplatelet agents (ticagrelor, prasugrel)?
    Varenhorst C; James S
    Curr Cardiol Rep; 2012 Aug; 14(4):486-92. PubMed ID: 22535473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and clinical use of prasugrel and ticagrelor.
    Ahmad S; Storey RF
    Curr Pharm Des; 2012; 18(33):5240-60. PubMed ID: 22724412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Ticagrelor Versus Prasugrel for Inflammation, Vascular Function, and Circulating Endothelial Progenitor Cells in Diabetic Patients With Non-ST-Segment Elevation Acute Coronary Syndrome Requiring Coronary Stenting: A Prospective, Randomized, Crossover Trial.
    Jeong HS; Hong SJ; Cho SA; Kim JH; Cho JY; Lee SH; Joo HJ; Park JH; Yu CW; Lim DS
    JACC Cardiovasc Interv; 2017 Aug; 10(16):1646-1658. PubMed ID: 28838475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiplatelet Therapy in Elderly Patients with Acute Coronary Syndromes: the Clopidogrel Revenge: Possible Reasons for a Bright Comeback.
    De Servi S; Landi A; Savonitto S
    Cardiovasc Drugs Ther; 2021 Apr; 35(2):399-401. PubMed ID: 32809109
    [No Abstract]   [Full Text] [Related]  

  • 10. One-Year Clinical Effectiveness Comparison of Prasugrel with Ticagrelor: Results from a Retrospective Observational Study using an Integrated Claims Database.
    Effron MB; Nair KV; Molife C; Keller SY; Page RL; Simeone JC; Murphy B; Nordstrom BL; Zhu Y; McCollam PL; Vetrovec GW
    Am J Cardiovasc Drugs; 2018 Apr; 18(2):129-141. PubMed ID: 29222628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiplatelet therapy in acute coronary syndromes.
    Grove EL; Würtz M; Thomas MR; Kristensen SD
    Expert Opin Pharmacother; 2015; 16(14):2133-47. PubMed ID: 26293612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A practical approach to prescribing antiplatelet therapy in patients with acute coronary syndromes.
    Alkhalil M; Kuzemczak M; Bell A; Stern S; Welsford M; Cantor WJ; Goodman SG
    CMAJ; 2022 Feb; 194(6):E205-E215. PubMed ID: 35165132
    [No Abstract]   [Full Text] [Related]  

  • 13. Safety and efficacy of IIb/IIIa inhibitors in combination with highly active oral antiplatelet regimens in acute coronary syndromes: A meta-analysis of pivotal trials.
    Roule V; Agueznai M; Sabatier R; Blanchart K; Lemaître A; Ardouin P; Collet JP; Milliez P; Montalescot G; Beygui F
    Platelets; 2017 Mar; 28(2):174-181. PubMed ID: 27657930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of prasugrel and ticagrelor in patients with acute coronary syndrome undergoing percutaneous coronary intervention: A meta-analysis of randomized and non-randomized studies.
    Watti H; Dahal K; Zabher HG; Katikaneni P; Modi K; Abdulbaki A
    Int J Cardiol; 2017 Dec; 249():66-72. PubMed ID: 29121759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prasugrel in the treatment of acute coronary syndrome.
    Spartalis M; Tzatzaki E; Spartalis E; Paschou SA; Athanasiou A; Iliopoulos DC; Siasos G; Voudris V
    Future Cardiol; 2020 Nov; 16(6):559-568. PubMed ID: 32390477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new era for antiplatelet therapy in patients with acute coronary syndrome.
    Dib C; Hanna EB; Abu-Fadel MS
    Am J Med Sci; 2010 Nov; 340(5):407-11. PubMed ID: 20818228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prasugrel vs. ticagrelor in acute coronary syndromes: which one to choose?
    Alber HF; Huber K; Pachinger O; Frick M
    Wien Klin Wochenschr; 2011 Aug; 123(15-16):468-76. PubMed ID: 21800048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clopidogrel, prasugrel or ticagrelor in patients with acute coronary syndromes undergoing percutaneous coronary intervention.
    Yudi MB; Clark DJ; Farouque O; Eccleston D; Andrianopoulos N; Duffy SJ; Brennan A; Lefkovits J; Ramchand J; Yip T; Oqueli E; Reid CM; Ajani AE;
    Intern Med J; 2016 May; 46(5):559-65. PubMed ID: 26909472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ticagrelor effectiveness overestimated by VASP index: platelet inhibition by ticagrelor versus prasugrel in acute coronary syndrome patients according to platelet function tests.
    Dillinger JG; Manzo Silberman S; Bal dit Sollier C; Amsallem M; Sideris G; Voicu S; Henry P; Drouet L
    Int J Cardiol; 2014 Sep; 176(2):557-9. PubMed ID: 25074556
    [No Abstract]   [Full Text] [Related]  

  • 20. Contemporary Time Trends in Use of Antiplatelet Agents Among Patients with Acute Coronary Syndrome and Comorbid Diabetes Mellitus or Chronic Kidney Disease.
    Desai RJ; Spoendlin J; Mogun H; Gagne JJ
    Pharmacotherapy; 2017 Oct; 37(10):1322-1327. PubMed ID: 28833345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.